Table 1.
Characteristics of the study population
| LT (n = 9) | ET (n = 29) | p values a | |
|---|---|---|---|
| Male/female (N) | 3/6 | 9/20 | 1.0000 |
| At ART start | |||
| Age (days) | 571 (254.5 to 630.5) | 110 (6.5 to 140) | <0.0001 |
| %CD4+ T cells | 24 (17 to 35) | 31 (20 to 43) | 0.4028 |
| Plasma HIV RNA (copies/µL) | 181.1 (55.6 to 620) | 110 (10.2 to 500) | 0.7295 |
| Time to suppression (months) | 1.6 (0.4 to 2.8) | 2.5 (0.3 to 5.2) | 0.3119 |
| At analysis | |||
| Age (years) | 9 (7.5 to 17.5) | 13 (9 to 16.5) | 0.4706 |
| % CD4+ T cells | 42 (34 to 46) | 39 (31.5 to 47) | 0.7872 |
| Plasma HIV RNA (copies/mL) | <40 | <40 | |
| HIV DNA (copies/106 PBMCs) | 112.4 (48.5 to 260.6) | 33.1 (0 to 74.7) | 0.0057 |
| Time on ART (years) | 8 (6 to 16) | 13 (9 to 16) | 0.2643 |
| CMV serology (N positive/negative) | 8/1 | 20/9 | 0.3958 |
Values are expressed as medians (interquartlile range, IQR) except number of individuals (N). CMV, cytomegalovirus. Clinical and demographic characteristics of the CARMA cohort divided into Early Treated patients (ET) and Late Treated patients (LT). p values in bold reached statistical significance (<0.05).
a
Calculated by Mann–Whitney U‐test; for categorical variables, Fisher's exact test was used.